anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized (the study drug is assigned by chance), double-blind (DB, neither physician nor patient knows the name of the assigned drug), multicenter, placebo-controlled, parallel group (each group of patients will be treated at the same time), dose-titration study. This study consists of a screening period, a DB phase (titration period and efficacy assessment period), and post-study phase. The study includes a 1 to 2-week screening period for wash-out of prohibited drugs, and screening for eligibility. Eligible patients will be randomly assigned to receive JNS001 or placebo in a ratio of 1:1. The study also includes a 4-week titration period. Patients will be titrated from a starting dose of 18 mg/day or matching placebo for 7 days (+/- 2 days), and continue with a weekly (+/- 2 days) increment of 18 mg until an individualized dose is achieved. Once an individualized dose is achieved, patients will remain on that dose for the rest of the titration period as far as tolerable. Doses can be tapered down only once during the titration period in the study, and their dose cannot be up-titrated again for the rest of the period. The 4-week titration period will be followed by the 4-week efficacy assessment period. The post-study phase for collection of additional safety data will be scheduled for 1 week after a patient's final study treatment. The study drug will be administered with water once daily in the morning at doses of 18 mg, 36 mg, 54 mg, 72 mg per day or the matching placebo. The study treatment period is 8 weeks (titration period of 4 weeks and efficacy assessment period of 4 weeks).
Respiratory dysfunction is a leading cause of death in individuals with spinal cord injuries (SCIs). Nearly one-quarter of all SCI cases involve injury to the upper spinal cord segments which impairs neural activation of the diaphragm muscle and compromises breathing. Although mechanical ventilation can be life-saving after cervical SCI (C-SCI), it also triggers rapid and profound diaphragm muscle atrophy, thereby complicating (or even preventing) ventilator weaning. Intramuscular diaphragm stimulation, or diaphragm pacing, was developed to replace long-term ventilator support and is now used acutely post C-SCI (\<4 months following injury) to promote ventilator weaning. This study will assess the effects of diaphragm stimulation on respiratory neural drive and breathing function in individuals with acute, traumatic C-SCI. Recording from these surgically implanted electrodes allows comparisons of electromyogram (EMG) recordings, in association with respiratory assessments, before and after short periods of diaphragm pacing to isolate the unique contribution of diaphragm pacing on neuromuscular diaphragm activation.
PURPOSE:To provide an antihyperlipemic agent containing hymecromone as an active component and having remarkably high pharmacological activity and safety. CONSTITUTION:Hymecromone (4-methylumbelliferone) of formula known as a cholagogue is used as an active component of an antihyperlipemic agent. The compound does not increase the body weight, exhibits antihyperlipemic action, and has extremely low toxicity and high safety. Accordingly, it can be administered to an animal or man singly or in combination with conventional drug carrier, e.g. in the form of an oral drug such as tablet, capsule, powder, etc. The dose of the compound to achieve the desired effect is usually 150-250mg of the compound daily for an adult by oral administration.
INTRODUCTION: Atrial fibrillation (AF) is often accompanied by comorbidities. Not only cardiovascular but also non-cardiovascular comorbidities have been associated with AF. Multimorbidity is therefore a common finding in patients with AF, especially in elderly patients. Multimorbidity is associated with adverse outcomes, adds complexity to AF management, and poses a significant burden on healthcare costs. It is expected that the prevalence of elderly patients with multimorbidity will increase significantly. It is therefore crucial to outline implications for clinical practice and guide comprehensive multimorbidity management.
AREAS COVERED: This perspective article outlines multimorbidity in AF and the importance of comprehensive comorbidity management. It addresses current clinical practice guided by international guidelines and the need for integrated care including a patient-centered focus, comprehensive AF management, coordinated multidisciplinary care, and supporting technology. Moreover, it proposes a novel model of care delivery following a systematic approach to multimorbidity management.
EXPERT OPINION: Providing comprehensive care by means of a multidisciplinary team and patient engagement is crucial to provide optimal personalized care for elderly patients with AF and multimorbidity. A systematic integrated care approach seems promising, but further studies are needed to investigate the feasibility of a systematic approach and prioritization of comorbidity management in patients with multimorbidity.
A normal pregnancy lasts between 37+0 to 41+6 weeks. Estimated date of delivery is set exactly at 40+0 weeks of gestation. Base on this estimation, professional society's guidelines have recommended to start inducing the labor from 41+0 to 41+6 weeks after the last menstrual period. Clinical practice during the last few decades has been moving towards this trend and postponing labor induction.

But is 40 weeks' gestational age the optimal endpoint of human pregnancy? Recent studies, however, showed different results where many of them support induction of labor at 39 weeks. A large cohort retrospective study which included information from merely 5.4 million non-anomalous live births in the United States from 2012 to 2016, though only modestly, the authors have been able to conclude that the rates of composite neonatal and maternal adverse outcomes increase from 39 through 41 weeks of gestation among low-risk parous women. Stratifying by parity, it seemed that the trend is also similar among all low-risk women no matter which parities they are in. When it comes to nulliparous women, results from a large prospective randomized control trial (the ARRIVE trial) show that induction of labor at 39 weeks in low-risk nulliparous women did not lead to significant lower frequency of a composite adverse perinatal outcome but it did result in a significant lower rate of cesarean delivery. More recently, in a review sponsored by the Cochrane library on induction of labor beyond 37 weeks' gestation has found that there is a clear reduction in perinatal death with a policy of labor induction at or beyond 37 weeks compared with expectant management, though absolute rates are small (0.4 versus 3 deaths per 1000). There were also lower caesarean rates without increasing rates of operative vaginal births and there were fewer Neonatal Intensive Care Unit admissions with a policy of induction. Base on these evidence, the American College of Obstetricians and Gynecologists has suggested "it's time to induce of labor at 39th week of gestation". It is true that although induction of labor is familiar with obstetricians, the procedure is still raising concern from patients' side. Even in the United States where patients consulting has been routinely applied, the rate of patients refuse to be induced at 39th week of gestation is about 50%. Review from Cochrane library also suggested that "Offering women tailored counselling may help them make an informed choice between induction of labor for pregnancies" . In some countries where the National Guidelines still recommends induction of labor should be considered after 41 weeks of gestation and pregnancy related decisions are driven by many identical factors such as: knowledge, traditional or cultural ones, the patients' perspective on induction of labor before 40 weeks of gestation is a challenge. Thus, the patients' understanding of the elective induction of labor and factors contribute to decision-making process towards induction of labor should be investigated in order not only to develop appropriate induction policies for the future but also scientific studies/randomized clinical trials to come.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to chemistry of biologically active polymers and preparing the sustained-release antibacterial preparations. Invention describes the novel complex of 1-(2-hydroxyethyl)-2- -methyl-5-nitroimidazole with polyvinylpyrrolidone of the formula (I)   where n = 81-539 (molecular mass is 9000- -60000 Da). Obtained complex shows the broad spectrum of antibacterial effect and can be used in suppurative surgery, gynecology, maxillofacial surgery and other branches of medicine as a drug. Invention describes also method of its preparing and pharmaceutical composition showing antibacterial effect. EFFECT: new complex indicated above, valuable antibacterial effect. 6 cl, 1 tbl, 3 ex
FIELD: biochemistry. SUBSTANCE: invention proposes polysaccharide of the general formula (C 6 H 12 O 6 ) 3-12 ·K 0,2-5  exhibiting characteristic maximum in UV-region (at 267-276 nm). Polysaccharide is isolated from the plant Ungernia Victor and can be prepared by an aqueous extraction of callus tissue biomass at its culturing (callus was obtained from plants of genus Ungernia). Polysaccharide shows capability to effect on functional activity of cells and cellular structures and can be used in medicine, veterinary science and applied biotechnology as a curative-prophylaxis and stimulating preparation. EFFECT: enhanced effectiveness of the preparation. 3 cl, 4 dwg
BACKGROUND: Multimodal breast cancer treatment may cause side effects reflected in patient-reported outcomes and/or symptom scores at the time of treatment planning for adjuvant radiotherapy. In our department, all patients have been assessed with the Edmonton Symptom Assessment System (ESAS; a questionnaire addressing 11 major symptoms and wellbeing on a numeric scale of 0-10) at the time of treatment planning since 2016. In this study, we analyzed ESAS symptom severity before locoregional radiotherapy.
PATIENTS AND METHODS: Retrospective review of 132 patients treated between 2016 and 2021 (all comers in breast-conserving or post-mastectomy settings, different radiotherapy fractionations) was performed. All ESAS items and the ESAS point sum were analyzed to identify subgroups with higher symptom burden and thus need for additional care measures.
RESULTS: The biggest patient-reported issues were fatigue, pain, and sleep problems. Patients with triple negative breast cancer reported a higher symptom burden (mean 30 versus 20, p = 0.038). Patients assigned to adjuvant endocrine therapy had the lowest point sum (mean 18), followed by those on Her-2-targeting agents without chemotherapy (mean 19), those on chemotherapy with or without other drugs (mean 26), and those without systemic therapy (mean 41), p = 0.007. Those with pathologic complete response after neoadjuvant treatment had significantly lower anxiety scores (mean 0.7 versus 1.8, p = 0.03) and a trend towards lower depression scores, p = 0.09.
CONCLUSION: Different surgical strategies, age, and body mass index did not impact on ESAS scores, while the type of adjuvant systemic therapy did. The effect of previous neoadjuvant treatment and unfavorable tumor biology (triple negative) emerged as important factors associated with symptom burden, albeit in different domains. ESAS data may facilitate identification of patients who should be considered for additional supportive measures to alleviate specific symptoms.
The purpose of this study is to determine whether urinary NGAL levels are able to distinguish the classical categories of renal disease. Previous studies have strongly suggested that this protein marks those with fulminant renal dysfunction with greater sensitivity and time resolution than currently used markers. Studies to date have been in highly selected populations: children and adults following cardiac surgery, infants with cardiovascular anomalies, and patients with known chronic kidney disease. Demonstration of similarly robust sensitivity and specificity in a broad Emergency Room population would strengthen the conception of NGAL as a marker of early or advancing kidney dysfunction. Most importantly, if NGAL can distinguish between types of renal disease at presentation in the ER, it might have important implications regarding ER management of these common presentations. For example, it could reduce diagnostic ambiguity and lag time from hours or days to seconds.
The invention discloses a set of polypeptide bound with gp120 protein, a polypeptide chip, and a preparation method and an application thereof. The set of polypeptide has high specific binding capacity with gp120 protein, such that the detection of gp120 protein at a low concentration can be realized. The polypeptide chip is prepared with a surface plasmon resonance (SPR) principle. When all molecules of the set of polypeptide are bound with a target, it is determined that the gp120 protein exists, and false-positive results during the experiment process are reduced. The invention also provides a medicine composition comprising the set of polypeptide. The invention has important application values in the diagnosis of diseases caused by HIV infection.
A composition adaptable to use in aerosol form for inhalation therapy comprises finely divided particles of a water-soluble acid addition salt of epinephrine or isoproterenol dispersed in a non-toxic liquid propellant, said particles being coated with a dispersing agent comprising oleyl alcohol or a mixture of oleyl alcohol with other fatty alcohols having from 12 to 22 carbon atoms.  The other alcohol may be myristyl, stearyl or cetyl alcohol. The propellant may be fluorinated or fluorochlorinated lower alkane or cycloalkane, or a mixture of such compounds; its preferred vapour pressure at 20-25 DEG C. is in the range 25 to 60 lb/square inch.ALSO:A composition adaptable to use in aerosol form for inhalation therapy comprises finely divided particles of a water-soluble acid addition salt of epinephrine or isoproterenol dispersed in a non-toxic liquid propellant, said particles being coated with a dispersing agent comprising oleyl alcohol or a mixture of olelyl alcohol with other fatty alcohols having from 12 to 22 carbon atoms.  The other alcohol may be myristyl, stearyl or cetyl alcohol.  The propellant may be a fluorinated or fluorochlorinated lower alkane or cycloalkane, or a mixture of such compounds; its preferred vapour pressure at 20-25 DEG C. is in the range 25 to 60 lbs./sq. in.
The invention belongs to the technical field of medical care, and particularly relates to a method for treating burns. The method comprises the step of preparing medicinal liquid consisting of huperzia serrata, kalanchoe verticillata elliot, begonia fimbristiplula hance, mazus japonicus, catharanthus roseus and distilled water. When treatment is performed, the medicinal liquid is uniformly applied to the periphery of a wound from top to bottom along the nerve end direction 4-6 times a day until the diseases disappear. The medicinal liquid has extremely strong permeability and has magic and unique curative effects on various skin burns and scalds, the wound feels fresh and cool after the medicinal liquid is applied, and the causalgia feeling immediately disappears. The medicinal liquid can be used for quickly minimizing hurt of the wound for a human body and even preventing a scar, and the original color of the skin can be recovered in several days. When the method is implemented, the process from medicinal liquid preparation to the treatment method is simple, low in comprehensive cost and excellent in curative effect, is a featured and remarkable folk medical natural therapy, and is worthy of great popularization.
Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental factors. However, the influence of genetic variation in immunosurveillance on cancer risk is not well understood. Leveraging population-level data from the UK Biobank and FinnGen, we show that heterozygosity at the human leukocyte antigen (HLA)-II loci is associated with reduced lung cancer risk in smokers. Fine-mapping implicated amino acid heterozygosity in the HLA-II peptide binding groove in reduced lung cancer risk, and single-cell analyses showed that smoking drives enrichment of proinflammatory lung macrophages and HLA-II+ epithelial cells. In lung cancer, widespread loss of HLA-II heterozygosity (LOH) favored loss of alleles with larger neopeptide repertoires. Thus, our findings nominate genetic variation in immunosurveillance as a critical risk factor for lung cancer.
The present invention relates to a mask for facial beauty, made of a silicon material in which germanium power and apatite are mixed at a proper ratio, and to a method for manufacturing the same. According to the present invention, the mask for facial beauty includes: a face unit in a three-dimensional oval shape corresponding to the shape of a face; a pair of band units which are formed to be integrally extended on both sides of the face unit; and a fixation means which are arranged on the band units and joins the band units with each other. The face unit includes: eye holes formed on locations corresponding to eye areas of the face; a protrusion which is located under the eye holes and is formed on a location corresponding to a nose area of a person; and a lip hole which is located under the protrusion and is formed on a location corresponding to a lip area of the face of the person. On one side of the protrusion, incised holes are formed on locations corresponding to nostrils of the person. The band units include ear holes formed by being partially cut on locations corresponding to ears of the person. The face unit and the band units are made of a silicon material, which is formed by mixing germanium power and apatite powder. According to the present invention, the mask for facial beauty is made of the silicon material and is formed to corresponding to the shape of the face. The germanium powder, which irradiates the face mask with a large amount of far-infrared rays and generates anions to remove waste on face skin and to prevent bacterial parasitism, and the apatite, which performs a catalyst action to make the far-infrared rays and the anions penetrate skin deeply, are mixed at a proper ratio. Therefore, the mask for facial beauty can promote health of face skin, can enhance beauty of face skin, and also can promote blood circulation.
PROAIR HFA (albuterol sulfate) Inhalation Aerosol is supplied as a pressurized aluminum canister with a red plastic actuator and white dust cap each in boxes of one. Each canister contains 8.5 g of the formulation and provides 200 actuations (NDC 21695-851-85). Each actuation delivers 120 mcg of albuterol sulfate from the canister valve and 108 mcg of albuterol sulfate from the actuator mouthpiece (equivalent to 90 mcg of albuterol base). 

SHAKE WELL BEFORE USE. Store between 15° and 25°C (59° and 77°F). Contents under pressure. Do not puncture or incinerate. Protect from freezing temperatures and prolonged exposure to direct sunlight. Exposure to temperatures above 120°F may cause bursting. For best results, canister should be at room temperature before use. Avoid spraying in eyes. Keep out of reach of children.

See FDA-Approved Patient Labeling (17.8) for priming and cleaning instructions.

The red actuator supplied with PROAIR HFA Inhalation Aerosol should not be used with the canister from any other inhalation aerosol products. The PROAIR HFA Inhalation Aerosol canister should not be used with the actuator from any other inhalation aerosol products.

The labeled amount of medication in each actuation cannot be assured after 200 actuations, even though the canister may not be completely empty. Discard the inhaler (canister plus actuator) after 200 actuations have been used. Never immerse the canister into water to determine how full the canister is ("float test").

PROAIR HFA Inhalation Aerosol does not contain chlorofluorocarbons (CFCs) as the propellant.
The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
The mechanism of action of selective serotonin reuptake inhibitors (SSRI) is still not properly established. It is essential to consider their positive and negative side effects before prescribing. In this article, we describe several of these side effects in the context of common pathologies and clinical situations. We discuss their cardioprotective effect and their role in the functional recovery of patients following stroke. We recall the increase in the risk of bleeding when prescribing SSRI concomitantly with antiaggregating and anticoagulant treatments. Prescribing SSRI also increases the risk of fracture and the frequency of hyponatremia. In the context of COPD, the effects of SSRI are more difficult to establish.
Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
PURPOSE:To provide the subject agent having significant anti-dandruff activity, and high in safety to the skin. CONSTITUTION:Tea leaves are either directly, or, as necessary, after finely chopped, subjected to extraction under heating in an alcohol such as methanol, ethanol, propylene glycol or 1,3-butylene glycol. The objective anti-dandruff agent contains the resultant extract as active ingredient. This extract can be directly used as an anti-dandruff agent; or may also be used in a diluted form using an appropriate base as diluent (in this case, the content of the extract in the diluent is 0.05-10wt.%, pref. 0.1-5wt.%). The anti-dandruff effect of this extract is drastically significant compared with those of extracts obtained from tea leaves using water at elevated temperatures or room temperature.
Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m\^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m\^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-management care of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning.